Clinical trial for Presbyopia
Official title Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
ClinicalTrials.gov ID: NCT07113210
What this study is testing
What is Qlosi (pilocarpine HCL ophthalmic solution) 0.4%?
an investigational eye drop being studied as a potential treatment for presbyopia is designed to stimulate the eye's muscles to constrict the pupil, which may increase depth of focus for near vision
Also referred to as pilocarpine.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether Qlosi (pilocarpine eye drops) improves quality of life for people with presbyopia.
- Who it's for
- You may be able to join if you have presbyopia and wear glasses or have dry eye.
- What's involved
- You will use Qlosi eye drops at home. You will fill out vision questionnaires at the start and after four weeks.
- Time commitment
- The study lasts about four weeks with visits at the start and at week four.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 to 64
You may be able to join if
- people who are 45-64 years old (inclusive) at the time of screening.
- Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any...
- Be able and willing to follow all instructions and attend study visits.
- Have text messaging capabilities on their phone.
- Self-reported complaints of near vision blur when fully corrected at distance.
You likely can't join if
- Known hypersensitivity to any ingredient in the study drops.
- Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).
- Any use of prescription eye drops 1 week before screening or during the study.
- Any past use of the study drops.
- Any contact lens use for the duration of the study.
- Artificial tears or lubricant eye drops use on the day of or during any study visits.
See the full eligibility criteria
- people who are 45-64 years old (inclusive) at the time of screening.
- Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.
- Be able and willing to follow all instructions and attend study visits.
- Have text messaging capabilities on their phone.
- Self-reported complaints of near vision blur when fully corrected at distance.
- Study confirmed near add that is between +0.75 D to +2.00 D OD/OS (inclusive).
- Spherical distance prescription between +1.00 D to -4.00 D OD/OS (inclusive).
- Cylinder power less than or equal to -1.00 D OD/OS.
- Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20/20 Snellen equivalent) or better OD/OS.
- Known hypersensitivity to any ingredient in the study drops.
- Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).
- Any use of prescription eye drops 1 week before screening or during the study.
- Any past use of the study drops.
- Any contact lens use for the duration of the study.
- Artificial tears or lubricant eye drops use on the day of or during any study visits.
- Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could...
- Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.
- A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.
- Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).
The study team makes the final eligibility decision.
Where it is enrolling
- Medina, Minnesota, United States
- Memphis, Tennessee, United States
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years to 64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Medina, Minnesota, United States; Memphis, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.